Airalzh intende investire una parte consistente dei fondi finanziando progetti di giovani ricercatori, volti alla ricerca di base e clinica sulla prevenzione e sulle fasi precoci della malattia di Alzheimer. Il Principal Investigator (PI) proponente deve avere un’età non superiore ai 40 anni al momento della chiusura del bando. Il PI potrà presentare una sola […]
L’obiettivo del bando è l’aumento del numero di trattamenti nuovi per la malattia di Alzheimer, le demenze correlate e l’invecchiamento cognitivo (studi clinici pilota basati su biomarker per i test di sicurezza di Alzheimer, così come i test di sicurezza di fase 1) Le proposte progettuali possono avere una durata variabile e il finanziamento massimo è
Alzheimer’s Drug Discovery Foundation – Program to Accelerate Clinical Trials (PACT) Leggi tutto »
Through its Prevention beyond the pipeline Program, the ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline. Duration: One year for epidemiological analyses Varies (multi-year) for clinical trials Average award: $50,000-$100,000 for epidemiological analyses
Alzheimer’s Drug Discovery Foundation – Prevention beyond the pipeline Leggi tutto »
Given the pathological heterogeneity of Alzheimer’s disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Clearly demonstrate target engagement for novel therapeutics The
Through its Drug Development Program the ADDF seeks to support develop therapeutics for Alzheimr’s disease and related dementias. Thsi program focuses on building preclinical evidence in animal models and on adavncing leas molecules to the clincal candidate selection stage. The propose studies shoudl have a high probability or reaching IND-enabling stuides within two years. Current
Alzheimer’s Drug Discovery Foundation – Drug Development Program Leggi tutto »
The Target Validation Pathfinder Grant scheme provides funds for small, translational research projects that show potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance. The lead applicant and point of contact must be based in an academic/research institution, either in the UK or abroad. Co-applicants from small and medium enterprises
Alzheimer’s Research UK – Target Validation Pathfinder Grant Leggi tutto »
Scoperta dai ricercatori della Fondazione EBRI ‘Rita Levi-Montalcini’ una molecola che ‘ringiovanisce’ il cervello bloccando l’Alzheimer nella prima fase: è l’anticorpo A13, che ringiovanisce appunto il cervello favorendo la nascita di nuovi neuroni e contrastando così i difetti che accompagnano le fasi precoci della malattia. Lo studio, italiano, è stato effettuato su topi che, così
Alzheimer, scoperta molecola che blocca la malattia Leggi tutto »
The lead applicant and point of contact must be a member of the Alzheimer’s Research UK Network. A Network cooperation application must include two or more Alzheimer’s Research UK Network Centres. It can also include researchers or institutions outside the UK. The Lead Applicant is expected to have a contract (fixed term or tenure) which covers the
Alzheimer’s Research UK – Network Cooperation Leggi tutto »
The Global Clinical Trials Fund covers: Studies that aim to demonstrate target engagement, Phase I or Phase II clinical trials undertaken to ascertain the potential safety and efficacy of (novel or re-purposed) drug-based interventions in human subjects Clinical trials of non-drug based, complex interventions Opportunities for research ‘add ons’ to ongoing clinical trials (e.g. validated
Alzheimer’s Research UK – Global Clinical Trials Fund Leggi tutto »
he Alzheimer’s Drug Discovery Foundation (ADDF) and The Association for Frontotemporal Degeneration (AFTD) seek to accelerate and support drug discovery for FTD and related dementias through this Request for Proposals (RFP). Priority areas for this program include: Neuroprotection Inflammation Proteostasis Mitochondria & metabolic function Vascular function Epigenetics APOE Synaptic activity and neurotransmitters Other aging target
Accelerating Drug Discovery for Frontotemporal Dementias Leggi tutto »
